Results of Evaluation of Four Cycles of Radionuclide Therapy with a Domestic Radiopharmaceutical Based on Radium-223 Chloride for the Treatment of Bone Metastases
- 作者: Sychev P.V.1, Udalov Y.D.1,2
-
隶属关系:
- Federal Scientific Clinical Center for Medical Radiology and Oncology
- A.I. Burnazyan Federal Medical Biophysical Center
- 期: 卷 70, 编号 2 (2025)
- 页面: 113-118
- 栏目: Nuclear Medicine
- URL: https://bakhtiniada.ru/1024-6177/article/view/361469
- DOI: https://doi.org/10.33266/1024-6177-2025-70-2-113-118
- ID: 361469
如何引用文章
全文:
详细
Purpose: The evaluation of the efficacy and safety of a domestic radiopharmaceutical drug based on Radium-223 chloride in patients with bone metastases in comparison with the original drug.
Material and methods: In the period from 2022 to 2023, a study was conducted that included 36 patients diagnosed with metastatic castration–resistant prostate cancer in the absence of visceral metastases, who underwent planar osteoscintigraphy in the whole body mode and PET/CT with 18F-PSMA. In all patients included in the study, the fact of metastatic skeletal lesions and the absence of visceral metastases were confirmed by diagnostic studies before inclusion in the study. The effectiveness was assessed by comparing the data of planar osteoscintigraphy and PET/CT before the start of treatment and after cycle 4, as well as by assessing the pain syndrome. The safety of the drug was monitored by assessing hematological toxicity in dynamics before and after each cycle. In the study group, 22 patients (84.6 %), and in the control group, 14 patients (93.3 %) received 4 cycles of treatment. The fatal outcome was found in the research group in 3 people (11.5 %), in the control group in 1 patient (6.7 %) with a diagnosis of Covid-19. The general condition of the patients at the time of the fourth treatment cycle was satisfactory, there were no side effects in the form of redness at the injection site, nausea and vomiting.
Results: There was a deviation from the lower limits of normal in the study group in terms of hemoglobin level in 9 patients (35 %), in the control group in 6 patients (40 %), in neutrophil levels in 1 patient in the study group (3.8 %), in platelet level in 6 patients in the study group (23 %), in 5 patients in the control group (33.3 %), in the level of lymphocytes in 6 patients in the study group (23 %), which is associated with the underlying disease. The minimum values of the indicators did not require correction.
Conclusions: The first results of therapy with a domestic drug based on radium-223 chloride are comparable with the original drug.
作者简介
P. Sychev
Federal Scientific Clinical Center for Medical Radiology and Oncology
Email: sychevpetr@gmail.com
Dimitrovgrad, Russia
Yu. Udalov
Federal Scientific Clinical Center for Medical Radiology and Oncology; A.I. Burnazyan Federal Medical Biophysical Center
Email: sychevpetr@gmail.com
Dimitrovgrad, Russia; Moscow, Russia
参考
- Lowrance W.T., Murad M.H., Oh W.K., Jarrard D.F., Resnick M.J., Cookson M.S. Castration-Resistant Prostate Cancer. AUA Guideline Amendment. J Urol. 2018 Dec;200;6:1264-1272. doi: 10.1016/j.juro.2018.07.090. Epub 2018 Aug 4. PMID: 30086276.
- Yau V., Chow E., Davis L., et al. Pain Management in Cancer Patients with Bone Metastases Remains a Challenge. J Pain Symptom Manage. 2004;27:1-3.
- Sartor O. Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: a New Beginning? J Clin Oncol. 2009;27:2417-2418.
- Bruland O.S., Nilsson S., Fisher D.R., et al. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the Alpha-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities. Clin Cancer Res. 2006;12:6250s-6257s.
- Henriksen G., Breistol K., Bruland O.S., et al. Significant Antitumor Effect from Bone-Seeking, Alpha-Particle-Emitting (223)Ra Demonstrated in an Experimental Skeletal Metastases Model. Cancer Res. 2002;62:3120-3125.
- Saad F., Carles J., Gillessen S., Heidenreich A., Heinrich D., Gratt J., Lévy J., Miller K., Nilsson S., Petrenciuc O., Tucci M., Wirth M., Federhofer J., O’Sullivan J.M. Radium-223 International Early Access Program Investigators. Radium-223 and Concomitant Therapies in Patients with Metastatic Castration-Resistant Prostate Cancer: an International, Early Access, Open-Label, Single-Arm Phase 3b trial. Lancet Oncol. 2016 Sep;17;9:1306-16. doi: 10.1016/S1470-2045(16)30173-5.
- Parker C., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M., Fosså S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall’Oglio M., Franzén L., Coleman R., Vogelzang N.J., O’Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø.S., Sartor O. ALSYMPCA Investigators. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013 Jul 18;369;3:213-23. doi: 10.1056/NEJMoa1213755.
- Shore N., Higano C.S., George D.J., et al. Concurrent or Layered Treatment with Radium-223 and Enzalutamide or Abiraterone/Prednisone: Real-World Clinical Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer Prostatic. 2020;23:680–688. doi: 10.1038/s41391-020-0236-0.
补充文件
